TG Therapeutics Q3 2026: Revenue $259.9M, Net Income $55.5M, $556.7M Cash
TGTX has more than doubled off its 52-week low of $26.76 on elevated volume (2.6× avg).
Summary
TG Therapeutics' Q3 2026 10-Q shows revenue of $259.9M, net income of $55.5M ($0.35 diluted EPS) and $556.7M in cash and investments, with $100.0M left on the buyback authorization.
Key Events · Earnings and Guidance · TGTX
-
Q3 Revenue Jumps 61%
Total revenue was $259.9M versus $161.7M a year ago, with BRIUMVI U.S. net sales of $232.6M and $7.4M to Neuraxpharm.
-
Operating Income $85.9M
Operating income reached $85.9M and net income $55.5M, or $0.35 diluted EPS; nine-month revenue was $705.2M.
-
Cash and Investments $556.7M
Cash, cash equivalents and investment securities totaled $556.7M at September 30, 2026, with nine-month operating cash flow of $66.6M.
-
Buyback $100.0M Remaining
The company repurchased 2,023,452 shares at an average of $49.43 in Q3, leaving $100.0M available under the $300M 2025 program.
Analysis · TGTX · Life Sciences
The 10-Q fills in the numbers behind this morning's 8-K headline. Q3 revenue of $259.9M (up from $161.7M a year ago) produced operating income of $85.9M and net income of $55.5M, or $0.35 diluted EPS. The balance sheet is the real story: $556.7M in cash and investment securities after a $750M Blue Owl term loan refinancing in March and roughly $200M of buybacks under the 2025 program, with $100.0M of repurchase capacity left. Nine-month operating cash flow turned positive at $66.6M versus a $44.4M outflow a year ago. The prior-year net income of $390.9M was inflated by a $371.7M deferred-tax valuation allowance release, so the year-over-year net income drop is an accounting comparison, not an operating deterioration.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TGTX was trading at $63.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $26.76 to $63.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.